Morningstar
RecommendedSign Up to Our Newsletters Open Window IconMorningstar's Guide to Investing in Stocks Arrow Right
Equity Research & Insights

Novartis and Alcon Finally Hit a Deal

We expect the acquisition will give Novartis increased exposure to the quickly growing eye-care business over the long run

Debbie S. Wang 15 December, 2010 | 5:20PM
Facebook Twitter LinkedIn
Font-Size

After approximately a year of circling each other and jockeying for position, Novartis (NOVN) and Alcon (ACL) have finally reached a mutually acceptable buyout price for the remaining 23% of Alcon that has been in the hands of minority shareholders. We will raise our fair value estimate for Alcon to match the new offer of $168 per share, which comprises 2.8 shares of Novartis and a contingent value amount in cash to lock in the $168 price if Novartis' shares trade above or below $60 at the close of the deal. The revised offer is modestly higher than the original $153 offer last January and on par with the average $168 price paid for Nestle's (NESN) entire Alcon stake. The revised offer is considerably higher than what Alcon is worth as a stand-alone entity. We think Alcon shareholders are getting a good deal, especially because Novartis shares remain undervalued and hold upside potential, in our view. It is unlikely that Alcon's independent directors could have changed the final outcome and prevented Novartis from purchasing full control of Alcon, but they could have dragged out the process. The new offer price is a graceful way for minority Alcon shareholders to halt their resistance to the buyout and move the process along in a timely manner.

We don't expect any major changes to our fair value estimate for Novartis based on the finalised purchase price of Alcon, which was close to our expectations. Also, we don't expect any significant changes to our AA+ credit rating based on completion of the deal and the announced CHF 10 billion share-buyback programme, as Novartis stated it will only repurchase shares to the point where it can maintain its double A credit rating. However, we expect Novartis' plans to repurchase shares in tandem with the completion of the Alcon acquisition will increase our 2011 earnings per share estimate by close to 4%, to $5.40, up 2% year over year. More important, over the long run, we expect the acquisition will give Novartis increased exposure to the quickly growing eye-care business (second only to oncology drug growth over the past five years).

Debbie S. Wang is an Equity Analyst with Morningstar. Senior Equity Analyst Damien Conover, CFA, contributed to this note.

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Facebook Twitter LinkedIn
Font-Size

About Author

Debbie S. Wang  Debbie S. Wang is a senior analyst with Morningstar.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures

The Morningstar Star Rating for Stocks is assigned based on an analyst's estimate of a stocks fair value. It is projection/opinion and not a statement of fact. Morningstar assigns star ratings based on an analyst’s estimate of a stock's fair value. Four components drive the Star Rating: (1) our assessment of the firm’s economic moat, (2) our estimate of the stock’s fair value, (3) our uncertainty around that fair value estimate and (4) the current market price. This process culminates in a single-point star rating that is updated daily. A 5-star represents a belief that the stock is a good value at its current price; a 1-star stock isn't. If our base-case assumptions are true the market price will converge on our fair value estimate over time, generally within three years. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in future and is no indication of future performance. For detail information about the Morningstar Star Rating for Stocks, please visit here

Quantitative Fair Value Estimate represents Morningstar’s estimate of the per share dollar amount that a company’s equity is worth today. The Quantitative Fair Value Estimate is based on a statistical model derived from the Fair Value Estimate Morningstar’s equity analysts assign to companies which includes a financial forecast of the company. The Quantitative Fair Value Estimate is calculated daily. It is a projection/opinion and not a statement of fact. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in future and is no indication of future performance. For detail information about the Quantiative Fair Value Estimate, please visit here

The Morningstar Medalist Rating is the summary expression of Morningstar’s forward-looking analysis of investment strategies as offered via specific vehicles using a rating scale of Gold, Silver, Bronze, Neutral, and Negative. The Medalist Ratings indicate which investments Morningstar believes are likely to outperform a relevant index or peer group average on a risk-adjusted basis over time. Investment products are evaluated on three key pillars (People, Parent, and Process) which, when coupled with a fee assessment, forms the basis for Morningstar’s conviction in those products’ investment merits and determines the Medalist Rating they’re assigned. Pillar ratings take the form of Low, Below Average, Average, Above Average, and High. Pillars may be evaluated via an analyst’s qualitative assessment (either directly to a vehicle the analyst covers or indirectly when the pillar ratings of a covered vehicle are mapped to a related uncovered vehicle) or using algorithmic techniques. Vehicles are sorted by their expected performance into rating groups defined by their Morningstar Category and their active or passive status. When analysts directly cover a vehicle, they assign the three pillar ratings based on their qualitative assessment, subject to the oversight of the Analyst Rating Committee, and monitor and reevaluate them at least every 14 months. When the vehicles are covered either indirectly by analysts or by algorithm, the ratings are assigned monthly. For more detailed information about these ratings, including their methodology, please go to here

The Morningstar Medalist Ratings are not statements of fact, nor are they credit or risk ratings. The Morningstar Medalist Rating (i) should not be used as the sole basis in evaluating an investment product, (ii) involves unknown risks and uncertainties which may cause expectations not to occur or to differ significantly from what was expected, (iii) are not guaranteed to be based on complete or accurate assumptions or models when determined algorithmically, (iv) involve the risk that the return target will not be met due to such things as unforeseen changes in changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rates, exchange rate changes, and/or changes in political and social conditions, and (v) should not be considered an offer or solicitation to buy or sell the investment product. A change in the fundamental factors underlying the Morningstar Medalist Rating can mean that the rating is subsequently no longer accurate.

For information on the historical Morningstar Medalist Rating for any managed investment Morningstar covers, please contact your local Morningstar office.

For more detailed information about conflicts of interest, including EU MAR disclosures, please see the “Morningstar Medalist Rating Analyst Conflict of Interest & Other Disclosures for EMEA”here

Select Your Site Edition To make sure the site is relevant to you, we need to know if you’re an individual investor or a financial professional.